There was no statistically significant difference in age, percentage of males, ECOG score, cancer treatment, D‐dimer, conduction disorder on ECG, decreased LVEF on TTE, Albumin/globulin, AST/ALT, LDL/HDL, time to the incidence of myocarditis, non‐cardiac immune‐related adverse events, past comorbidities, myocarditis treatment and mortality between the two groups (Table 4). This evidence concerns the gene GPT and conduct disorder.